Feb. 26 Quick Takes: Takeda acquires PvP for celiac therapy; plus Lilly, Esperion, Supernus, Moderna, Taiho-Arcus, Twist-Sophia

Takeda gains another celiac candidate via PvP takeout

After PvP Biologics Inc. finished a Phase I trial demonstrating proof of concept of its celiac disease therapy, Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) exercised its option to acquire the biotech for an undisclosed upfront payment plus up to $330 million in milestones. TAK-062 (formerly Kuma062), a gluten-degrading

Read the full 562 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE